Enhancing Cause of Death Prediction: Development and Validation of Machine Learning Models Using Multimodal Data Across Multiple Health-Care Sites Read more about Enhancing Cause of Death Prediction: Development and Validation of Machine Learning Models Using Multimodal Data Across Multiple Health-Care Sites
Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations Read more about Active Surveillance of Medical Product Use in the FDA’s Sentinel System: A Focus on Pediatric Populations
Utilization of Orally Ingestible Systemic Sodium Fluoride: A Descriptive Analysis Read more about Utilization of Orally Ingestible Systemic Sodium Fluoride: A Descriptive Analysis
Strengthening Inferential Studies in the FDA Sentinel Initiative: Results from a Methodological Demonstration Project Read more about Strengthening Inferential Studies in the FDA Sentinel Initiative: Results from a Methodological Demonstration Project
Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof-of-Principle Analysis Read more about Evaluating Unmeasured Confounding Factors in Claims Data Using Linked Electronic Health Records: A Proof-of-Principle Analysis
FDA Labeling Change: KEPPRA Updated to Include Risk of Anaphylaxis and Angioedema Read more about FDA Labeling Change: KEPPRA Updated to Include Risk of Anaphylaxis and Angioedema
Renal Cell Carcinoma Algorithm Defined in "Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators" Read more about Renal Cell Carcinoma Algorithm Defined in "Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators"
Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators Read more about Renal Cell Carcinoma Following At Least 180 Days of Canagliflozin Use in Patients with Type 2 Diabetes Mellitus: A Clone-Censor-Weighted Analysis with Inverse Probability of Treatment Weighting for Active Comparators
Assessment of ARIA Sufficiency: Symbravo (meloxicam and rizatriptan) Read more about Symbravo (meloxicam and rizatriptan)